Ekso Bionics Holdings Inc (EKSO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ekso Bionics Holdings Inc (EKSO) has a cash flow conversion efficiency ratio of -0.370x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($5.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ekso Bionics Holdings Inc to measure how much of total assets are equity-financed.
Ekso Bionics Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ekso Bionics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ekso Bionics Holdings Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Ekso Bionics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ekso Bionics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Azimut Exploration Inc.
V:AZM
|
-0.037x |
|
Farm Pride Foods Ltd
AU:FRM
|
0.183x |
|
EPE Capital Partners Ltd
JSE:EPE
|
-0.059x |
|
Hastings Technology Metals Ltd
AU:HAS
|
-0.035x |
|
Brand Group (M.G) Ltd
TA:BRND
|
0.030x |
|
Canlan Ice Sports Corp.
TO:ICE
|
0.085x |
|
Infrea AB
ST:INFREA
|
-0.046x |
|
Hana Must SPAC 2
KQ:208370
|
0.013x |
Annual Cash Flow Conversion Efficiency for Ekso Bionics Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ekso Bionics Holdings Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ekso Bionics Holdings Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.03 Million | $-11.80 Million | -1.307x | -68.72% |
| 2024-12-31 | $12.71 Million | $-9.85 Million | -0.775x | +18.97% |
| 2023-12-31 | $12.61 Million | $-12.05 Million | -0.956x | -65.63% |
| 2022-12-31 | $25.44 Million | $-14.69 Million | -0.577x | -92.61% |
| 2021-12-31 | $37.22 Million | $-11.16 Million | -0.300x | +84.82% |
| 2020-12-31 | $4.43 Million | $-8.76 Million | -1.975x | +14.91% |
| 2019-12-31 | $6.80 Million | $-15.77 Million | -2.320x | +71.44% |
| 2018-12-31 | $2.73 Million | $-22.16 Million | -8.125x | -456.59% |
| 2017-12-31 | $21.39 Million | $-31.23 Million | -1.460x | +61.86% |
| 2016-12-31 | $6.53 Million | $-25.00 Million | -3.827x | -84.53% |
| 2015-12-31 | $8.81 Million | $-18.27 Million | -2.074x | -215.12% |
| 2014-12-31 | $22.80 Million | $-15.01 Million | -0.658x | +17.39% |
| 2013-12-31 | $15.05K | $-11.99K | -0.797x | 0.00% |
| 2012-12-31 | $15.05K | $-11.99K | -0.797x | -- |
About Ekso Bionics Holdings Inc
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It … Read more